UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 OR 15 (d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) - ~~September~~November 1513, 2009

NUCRYST PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)


Alberta, Canada	000-51686	Not Applicable
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

NUCRYST Pharmaceuticals Corp.

101 College Road East

Princeton, New Jersey 08540

(Address of principal executive offices)

Registrant’s telephone number, including area code: (609) 228-8210

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 32.0102 ~~Notice~~Results of ~~Delisting~~Operations orand ~~Failure~~Financial ~~to Satisfy a Continued Listing Rule or Standard; Transfer of Listing~~Condition.

On ~~September~~November 1513, 2009, NUCRYST Pharmaceuticals Corp. (the “Company”) ~~received~~issued a ~~deficiency~~press ~~notice~~release ~~from~~announcing ~~the~~its ~~Nasdaq~~financial ~~Stock~~results ~~Market (“Nasdaq”) stating that it no longer complies with Nasdaq Listing Rule 5550(a)(2) because,~~ for the ~~previous~~quarter 30ended ~~consecutive~~September ~~business days~~30, ~~the~~2009. The ~~bid~~press ~~price~~release ofis ~~its~~attached ~~common~~hereto ~~shares~~as ~~had~~Exhibit ~~closed below~~99.1 ~~the~~and ~~minimum~~is ~~requirement~~incorporated ofherein ~~$1.00~~by ~~per share~~reference.

The ~~notice~~information ~~also~~in ~~indicated~~this ~~that~~Current inReport ~~accordance~~on ~~with~~Form ~~Listing~~8-K, ~~Rule~~including ~~5810(c)(3)(A)~~ the ~~Company~~exhibit ~~has~~attached ~~until~~hereto, ~~March~~is ~~15,~~being ~~2010~~furnished to ~~regain~~the ~~compliance,~~United ~~which~~States ~~requires~~Securities aand ~~closing~~Exchange ~~bid~~Commission ~~price of~~ (the ~~Company’s~~“SEC”) ~~common~~and ~~stock~~shall atnot orbe ~~above~~deemed ~~$1.00~~to ~~per~~be ~~share~~“filed” for aany ~~minimum~~purpose, ofnor 10shall ~~consecutive~~such ~~business~~information ~~days. In~~or ~~the~~such ~~event~~exhibit ~~the~~be ~~Company~~deemed ~~does~~of ~~not~~incorporated ~~regain~~by reference ~~compliance~~in ~~within~~any ~~this~~filing ~~period,~~with ~~Nasdaq~~the ~~will~~SEC ~~issue~~made aby ~~written notification that~~ the Company’s ~~shares~~under ~~are subject to delisting. If~~ the ~~Company~~Securities isExchange ~~not~~Act ~~deemed~~of in1934, ~~compliance~~or ~~prior~~the toSecurities ~~March~~Act ~~15,~~of ~~2010~~1933, ~~but~~whether ~~demonstrates~~made ~~that~~before itor ~~meets~~after ~~all~~the ~~applicable~~date ~~standards~~hereof, ~~for~~regardless ~~initial~~of ~~listing~~any ongeneral ~~The~~incorporation ~~Nasdaq~~language ~~Capital~~in ~~Market (except the bid price requirement) on~~ such ~~date~~filing, itunless ~~will~~expressly beset ~~afforded~~forth anby ~~additional~~specific ~~180~~reference ~~day~~to ~~compliance period. The notice has no effect on the listing of the Company’s shares at~~ this ~~time~~filing.

The Company is currently evaluating its alternatives to resolve the listing deficiency.

On September 18, 2009, the Company issued a press release announcing the receipt of the Nasdaq deficiency notice, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit
Number		Description
99.1		Press Release, dated ~~September~~November 1813, 2009, titled “NUCRYST ~~Receives~~announces ~~deficiency~~2009 ~~Notice~~third ~~from~~quarter ~~NASDAQ~~financial results.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nucryst Pharmaceuticals Corp.
	By:	/s/ Carol L. Amelio
		Carol L. Amelio
		Vice President, General Counsel and Corporate Secretary
Dated: September 18, 2009
Dated: November 13, 2009

EXHIBIT INDEX

Exhibit
Number		Description
99.1		Press Release, dated September 18, 2009, titled “NUCRYST Receives deficiency Notice from NASDAQ”

Filing Compare · NUCRYST Pharmaceuticals Corp.